3 patents currently held
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2036. from the record
Of the 14 now held by other companies, 11 name Seattle Project Corp. as their current owner, and 3 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2036
Next term end
1
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Dec 2036 · High confidence
The most cited patent in this portfolio, cited by 24 later US patents, top 25% of utility patents granted in 2018 in our data. Protection runs to 2036.
now held by Seattle Project Corp.
Also notable
Ends May 2038 · High confidence
Cited by 9 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
now held by Seattle Project Corp.
Also notable
Ends Jun 2040 · Medium confidence
Cited by 4 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2040.
now held by Seattle Project Corp.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- Sep 11Assignment recorded on 8 records: Gritstone Bio, Inc. to Nexoplex Bio LLC Recorded Sep 11, 2026, executed Jan 28, 2026. Conveyance as recorded: Corporate Conversion with Change of Name. A recorded assignment is a filed document, not a statement of current ownership. Reel 76442, frame 329.
- 1 of the patents on this record was granted since Aug 18, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Neoantigen Identification, Manufacture, and Use | 3 in force | to Dec 2036 |
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,847,252 | Neoantigen Identification, Manufacture, and Use In force · High confidence | In force | High confidence | |
| US 10,847,253 | Neoantigen identification, manufacture, and use In force · High confidence | In force | High confidence | |
| US 11,183,286 | Neoantigen Identification, Manufacture, and Use In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 14 patents in force now held by others · 38 applications pending · 11 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
3 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.